159877-95-9Relevant academic research and scientific papers
Viracept (nelfinavir mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 protease
Kaldor, Stephen W.,Kalish, Vincent J.,Davies II, Jay F.,Shetty, Bhasker V.,Fritz, James E.,Appelt, Krzysztof,Burgess, Jeffrey A.,Campanale, Kristina M.,Chirgadze, Nickolay Y.,Clawson, David K.,Dressman, Bruce A.,Hatch, Steven D.,Khalil, Deborah A.,Kosa, Maha B.,Lubbehusen, Penny P.,Muesing, Mark A.,Patick, Amy K.,Reich, Siegfried H.,Su, Kenneth S.,Tatlock, John H.
, p. 3979 - 3985 (2007/10/03)
Using a combination of iterative structure-based design and an analysis of oral pharmacokinetics and antiviral activity, AG1343 (Viracept, nelfinavir mesylate), a nonpeptidic inhibitor of HIV-1 protease, was identified. AG1343 is a potent enzyme inhibitor
HIV protease inhibitors
-
, (2008/06/13)
HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain the
HIV protease inhibitors
-
, (2008/06/13)
HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
Intermediate and process for making
-
, (2008/06/13)
The present invention provides novel HIV protease inhibitors, pharmaceutical formulations containing those compounds and methods of treating and/or preventing HIV infection and/or AIDS.
